Monoclonal Anti-FANCD2 antibody produced in mouse

Fanconi anemia complementation group D2 (FANCD2) is encoded by the gene mapped to human chromosome 3p25.3.

Human FANCD2 fusion protein

For WB: Use at a dilution of 1:500-1:3000. For ELISA: Use at an assay dependent dilution. Optimal dilutions/concentrations should be determined by the researcher.

Fanconi Anemia Complementation Group D2 (FANCD2) protein is one of at least six factors shown to be involved in the autosomal-recessive cancer-prone disorder, Fanconi Anemia (FA). FA group D has been shown to be comprised of two separate proteins, FANCD1 and FANCD2. Mutations in BRCA2 can cause FANCD1. FANCD2 has been shown to colocalize with BRCA1 in ionizing radiation-induced foci. FANCD2 is involved in genomic resistance to DNA cross-linking reagents, and the arrest of DNA synthesis following exposure to ionizing radiation. FANCD2 has been shown to directly interact with NBS1

Fanconi anemia complementation group D2 (FANCD2) is implicated in countering endogenous levels of replication stress, which is required for maintenance of genomic stability. FANCD2 plays a crucial role in fanconi anemia (FA) pathway. It is also involved in the regulation of human papillomavirus (HPV) replication. Overexpression of the gene has been observed in hepatocellular carcinoma (HCC). Thus, it can be considered as a potential biomarker for poor prognosis and therapeutic target for HCC.

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Phosphate-buffered saline, no preservative added.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.